Following on from information provided to NICE by the company in June 2018, the appraisal of Atherothrombotic events - vorapaxar was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 616 |
| Referral date | 01 November 2014 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | 01 January 2100 |
Project Team
| Associate Director: | TBC |
| Communications manager: | TBC |
| Project manager: | TBC |
| Technical Advisor: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in June 2018, the appraisal of Atherothrombotic events - vorapaxar was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 December 2014 |
Please note that following on from information received from the company, this appraisal will be rescheduled to align with the commercial availability of the product within the UK. Therefore, NICE has decided to suspend this appraisal from its current work programme for the time being. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual